drugset / Trial / NCT00511719

Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes

NCT00511719

Phase 2 Completed 13 enrolled Mannkind Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the kinetics and biodynamics of inhaled Technosphere Insulin with those of subcutaneous (SC) regular human insulin.

Timeline

Start
2004-02
Primary completion
2004-04
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Protein / enzyme biologic 24 iu Subcutaneous
Comparator Insulin Protein / enzyme biologic 48 iu Inhaled